JP2020535165A5 - - Google Patents

Download PDF

Info

Publication number
JP2020535165A5
JP2020535165A5 JP2020517472A JP2020517472A JP2020535165A5 JP 2020535165 A5 JP2020535165 A5 JP 2020535165A5 JP 2020517472 A JP2020517472 A JP 2020517472A JP 2020517472 A JP2020517472 A JP 2020517472A JP 2020535165 A5 JP2020535165 A5 JP 2020535165A5
Authority
JP
Japan
Prior art keywords
optionally substituted
case
hydrogen
alkyl
substituted alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020517472A
Other languages
English (en)
Japanese (ja)
Other versions
JP7350337B2 (ja
JP2020535165A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/052913 external-priority patent/WO2019067587A1/en
Publication of JP2020535165A publication Critical patent/JP2020535165A/ja
Publication of JP2020535165A5 publication Critical patent/JP2020535165A5/ja
Application granted granted Critical
Publication of JP7350337B2 publication Critical patent/JP7350337B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020517472A 2017-09-26 2018-09-26 神経障害の処置においてranタンパク質レベルを低下させるためのメトホルミンおよびそのアナログの使用 Active JP7350337B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762563588P 2017-09-26 2017-09-26
US62/563,588 2017-09-26
PCT/US2018/052913 WO2019067587A1 (en) 2017-09-26 2018-09-26 USE OF METFORMIN AND ANALOGUES THEREOF TO REDUCE RAN PROTEIN RATES DURING TREATMENT OF NEUROLOGICAL DISORDERS

Publications (3)

Publication Number Publication Date
JP2020535165A JP2020535165A (ja) 2020-12-03
JP2020535165A5 true JP2020535165A5 (enExample) 2021-11-04
JP7350337B2 JP7350337B2 (ja) 2023-09-26

Family

ID=65903814

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020517472A Active JP7350337B2 (ja) 2017-09-26 2018-09-26 神経障害の処置においてranタンパク質レベルを低下させるためのメトホルミンおよびそのアナログの使用

Country Status (6)

Country Link
US (2) US11903910B2 (enExample)
EP (1) EP3688021A4 (enExample)
JP (1) JP7350337B2 (enExample)
AU (1) AU2018342105B2 (enExample)
CA (1) CA3076214A1 (enExample)
WO (1) WO2019067587A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10295547B2 (en) 2013-03-14 2019-05-21 University Of Florida Research Foundation, Incorporated Use and treatment of di-amino acid repeat-containing proteins associated with ALS
US10509045B2 (en) 2015-05-29 2019-12-17 University Of Florida Research Foundation, Incorporated Methods for diagnosing Huntington's disease
EP3440100A4 (en) 2016-04-04 2020-01-22 University of Florida Research Foundation, Incorporated HANDLING EIF3 TO MODULATE A NON-ATG TRANSLATION ASSOCIATED WITH A REPETITION (RAN)
AU2018255293B2 (en) 2017-04-17 2024-03-07 University Of Florida Research Foundation, Incorporated Regulation of RAN translation by PKR and eIF2a-P pathways
US12504380B2 (en) 2017-09-25 2025-12-23 University Of Florida Research Foundation, Incorporated Immunoassays for detection of ran proteins
CA3076214A1 (en) 2017-09-26 2019-04-04 University Of Florida Research Foundation, Incorporated Use of metformin and analogs thereof to reduce ran protein levels in the treatment of neurological disorders
EP3994159A4 (en) * 2019-07-05 2023-08-09 University of Florida Research Foundation, Incorporated METHODS OF TREATING NEUROLOGICAL DISEASES ASSOCIATED WITH THE RAN PROTEIN
AU2020348916B2 (en) 2019-09-20 2025-12-18 University Of Florida Research Foundation, Incorporated Detection of antibodies against RAN proteins from serum and tissue lysates
EP4129293A4 (en) * 2020-03-27 2024-04-03 Kyoto University Nerve cell degeneration inhibitor
US20250041247A1 (en) 2021-12-01 2025-02-06 University Of Florida Research Foundation, Incorporated Small molecule inhibitors of repeat associated non-aug (ran) translation and combination therapies
WO2025179209A1 (en) * 2024-02-22 2025-08-28 Whitehead Institute For Biomedical Research Methods and agents to study and restore suppressed protein mobility in disease

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
EA000736B1 (ru) 1995-04-11 2000-02-28 Мерк Энд Ко., Инк. Способ получения дипептидов
JP2002513295A (ja) 1997-07-08 2002-05-08 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド 123種類のヒト分泌タンパク質
US6362007B1 (en) 1997-08-29 2002-03-26 Innogenetics N.V. Methylated, SMD homologous peptides, reactive with the antibodies from sera of living beings affected with systemic lupus erythematosus
US6413783B1 (en) 1997-09-18 2002-07-02 Meso Scale Technologies, Llc Assay sonication apparatus and methodology
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
CA2407352A1 (en) 2000-04-21 2001-11-01 Corixa Corporation Compositions and methods for the therapy and diagnosis of acne vulgaris
EP1385861A2 (en) 2000-10-25 2004-02-04 Diadexus, Inc. Compositions and methods relating to lung specific genes and proteins
AU2002219988A1 (en) 2000-11-20 2002-05-27 Diadexus, Inc. Compositions and methods relating to breast specific genes and proteins
US7528227B2 (en) 2004-03-23 2009-05-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Histone H2A peptide derivatives and uses thereof
US7163943B2 (en) 2001-09-21 2007-01-16 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7314974B2 (en) 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
DK3211085T3 (da) 2003-09-30 2021-06-21 Univ Pennsylvania Klader af adeno-associeret virus (aav), sekvenser, vektorer indeholdende disse og anvendelser deraf
AU2005222776A1 (en) 2003-12-31 2005-09-29 Genimmune N.V. Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
US7481997B1 (en) 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
JP4878551B2 (ja) 2004-04-08 2012-02-15 貞和 相磯 運動ニューロン疾患治療薬
US20060068434A1 (en) 2004-09-21 2006-03-30 Jay Stoerker Methods and compositions for detecting cancer using components of the U2 spliceosomal particle
AU2006210973A1 (en) 2005-01-31 2006-08-10 University Of Iowa Research Foundation Nucleic acid silencing of Huntington's Disease gene
WO2006133194A2 (en) 2005-06-06 2006-12-14 Vgx Pharmaceuticals, Inc Methods for treating viral infection with oral or injectible drug solution
MX2008006204A (es) 2005-11-11 2008-10-17 Aurogen Inc Metodo para tratar por medio de la administracion de insulina la enfermedad o el trastorno del sistema nervioso central asociado con el encogimiento de tejido o atrofia.
ES2453374T3 (es) 2006-09-20 2014-04-07 The Queen's University Of Belfast Método para determinar si una célula tumoral presenta potencial invasivo y/o metastásico, y agentes moduladores de la transformación maligna
US20080188457A1 (en) 2007-02-02 2008-08-07 Braincells, Inc. Modulation of Neurogenesis with Biguanides and GSK3-beta Agents
US20090143418A1 (en) 2007-11-30 2009-06-04 The Regents Of The University Of Michigan Compositions and Methods for Preventing and Treating Hair Growth Cycle-Related Conditions
GB0809821D0 (en) 2008-05-30 2008-07-09 Univ Aberdeen Treatment and diagnosis of behavioural disorders
TW201034684A (en) 2009-02-18 2010-10-01 Genentech Inc Method for inhibiting neurodegeneration
US20130115603A9 (en) 2009-04-02 2013-05-09 Regents Of The University Of Minnesota Nucleotide repeat expansion-associated polypeptides and uses thereof
DK2419144T3 (da) 2009-04-17 2019-10-21 Univ Oxford Innovation Ltd Sammensætning til levering af genetisk materiale
US8993633B2 (en) * 2009-05-18 2015-03-31 Fate Therapeutics, (Canada) Inc. Treatment of muscle disease characterized by insulin resistance
WO2011028912A2 (en) 2009-09-03 2011-03-10 University Of Tennessee Research Foundation A biomarker for neurodegeneration in neurological disease
EP2552435A1 (en) 2010-04-02 2013-02-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions comprising ampk activator (metformin/troglitazone) for the treatment of myotonic dystrophy type 1 (dm1)
EP3202914B2 (en) 2011-08-31 2023-06-28 The University of Manchester Method for treating a neurodegenerative disease
NZ629427A (en) 2012-02-29 2016-04-29 Sangamo Biosciences Inc Methods and compositions for treating huntington’s disease
KR101417272B1 (ko) 2012-05-15 2014-07-14 경상대학교산학협력단 메트포민 및/또는 타이모퀴논을 포함하는 임신중 알코올 노출에 의한 신경질환 치료 또는 예방용 약학적 조성물
US20140100282A1 (en) 2012-10-10 2014-04-10 Patrick S L Wong Intranasal administration of pharmaceutical agents for treatment of neurological diseases
WO2014114303A1 (en) 2013-01-22 2014-07-31 Deutsches Zentrum Für Neurodegenerative Erkrankungen Dipeptide-repeat proteins as therapeutic target in neurodegenerative diseases with hexanucleotide repeat expansion
LT2948777T (lt) 2013-01-22 2019-09-25 Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. Baltymai su pasikartojančiais dipeptidais, kaip terapinis taikinys neurodegeneracinių ligų su padidėjusiu heksanukleotidų pasikartojimu atveju
US9448232B2 (en) 2013-01-24 2016-09-20 Mayo Foundation For Medical Education And Research Methods and materials for detecting C9ORF72 hexanucleotide repeat expansion positive frontotemporal lobar degeneration or C9ORF72 hexanucleotide repeat expansion positive amyotrophic lateral sclerosis
US10295547B2 (en) 2013-03-14 2019-05-21 University Of Florida Research Foundation, Incorporated Use and treatment of di-amino acid repeat-containing proteins associated with ALS
CA2904794C (en) 2013-03-15 2021-11-23 Peter Walter Modulators of the eif2alpha pathway
WO2014186746A1 (en) 2013-05-16 2014-11-20 University Of Florida Research Foundation, Inc. HAIRPIN mRNA ELEMENTS AND METHODS FOR THE REGULATION OF PROTEIN TRANSLATION
EP2837390A1 (en) 2013-08-15 2015-02-18 Universitäts-Kinderspital beider Basel Combined Pharmaceutical Preparation for Use in Treating Neuromuscular Disorders
CA2990161A1 (en) 2014-08-13 2016-02-18 The Scripps Research Institute Treatment of c9ftd/als by targeting rna expanded repeat sequences
WO2016191241A1 (en) 2015-05-27 2016-12-01 Mmc & Company Llc Dual target mitochondrial impinging pharmaceutical compositions affecting mitochondrial redox state and methods of treatment
US10509045B2 (en) 2015-05-29 2019-12-17 University Of Florida Research Foundation, Incorporated Methods for diagnosing Huntington's disease
EP3440100A4 (en) 2016-04-04 2020-01-22 University of Florida Research Foundation, Incorporated HANDLING EIF3 TO MODULATE A NON-ATG TRANSLATION ASSOCIATED WITH A REPETITION (RAN)
MX2019001937A (es) * 2016-08-18 2019-10-02 Ovid Therapeutics Inc Métodos de tratamiento de trastornos del desarrollo con biguanidas.
AU2018255293B2 (en) 2017-04-17 2024-03-07 University Of Florida Research Foundation, Incorporated Regulation of RAN translation by PKR and eIF2a-P pathways
US12504380B2 (en) 2017-09-25 2025-12-23 University Of Florida Research Foundation, Incorporated Immunoassays for detection of ran proteins
CA3076214A1 (en) 2017-09-26 2019-04-04 University Of Florida Research Foundation, Incorporated Use of metformin and analogs thereof to reduce ran protein levels in the treatment of neurological disorders
EP3994159A4 (en) 2019-07-05 2023-08-09 University of Florida Research Foundation, Incorporated METHODS OF TREATING NEUROLOGICAL DISEASES ASSOCIATED WITH THE RAN PROTEIN
AU2020348916B2 (en) 2019-09-20 2025-12-18 University Of Florida Research Foundation, Incorporated Detection of antibodies against RAN proteins from serum and tissue lysates

Similar Documents

Publication Publication Date Title
JP2020535165A5 (enExample)
JP2019094345A5 (enExample)
JP2019031560A5 (enExample)
JP2020511461A5 (enExample)
JP2018150331A5 (enExample)
JP2019524883A5 (enExample)
JP2019034943A5 (enExample)
JP2017535586A5 (enExample)
JP2020519606A5 (enExample)
JP2017537940A5 (enExample)
JP2020502047A5 (enExample)
JP2013542267A5 (enExample)
JP2008513516A5 (enExample)
JP2009524691A5 (enExample)
JP2019531279A5 (enExample)
JP2018509438A5 (enExample)
JP2006507355A5 (enExample)
JP2010523623A5 (enExample)
JP2010524899A5 (enExample)
JP2006509842A5 (enExample)
JP2020128426A5 (enExample)
CN109790145A (zh) 二氢嘧啶类化合物及其制备方法和用途
JP2010527985A5 (enExample)
JP2020516616A5 (enExample)
JP2018507230A5 (enExample)